Welcome!

News Feed Item

APAC NSCLC and Epilepsy Therapeutics Market 2019 Forecasts

DALLAS, March 15, 2014 /PRNewswire/ --

ReportsnReports.com offers "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability" and "NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool" research reports in its store.

According to Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability research report available at http://www.reportsnreports.com/reports/276612-epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability.html, the value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.

The NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool report, available at http://www.reportsnreports.com/reports/276615-nsclc-therapeutics-in-asia-pacific-markets-to-2019-personalized-therapies-focus-on-untapped-segment-of-squamous-cell-carcinoma-to-expand-treatment-pool.html, says NSCLC market in the APAC region is estimated to have been worth $1.8 billion in 2012 and is expected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% to reach $2.9 billion by 2019. The key drivers for this growth include an aging population, an increasing number of NSCLC incident cases and the expected launch of promising therapies. The launch of premium-priced novel antibodies and immunotherapies in the first and second lines of therapy, including Boehringer Ingelheim's Gilotrif, Eli Lilly's necitumumab, Bristol-Myers Squibb's Yervoy (ipilimumab) and nivolumab, Pfizer's dacomitinib and Novartis's LDK378 are set to drive the market during the forecast period. However, the recent implementation of a price ceiling on essential drugs,dominance of generic drugs in India and expected pricing restrictions in China could curtail the NSCLC market in APAC countries.

China and India are expected to show the fastest growth over the forecast period for Asia-Pacific epilepsy therapeutics market, with CAGRs of 6.1% and 4.2%, respectively. Meanwhile, Australia and Japan will witness slightly lower CAGRs of 3.9% and 1.7%. Research states that the epilepsy sector is still dominated by older generation Anti-Epileptic Drugs (AEDs), such as carbamazepine, valproate, oxcarbazepine and phenytoin, which account for a combined share of over 60% of the APAC region's market. Historically, these AEDs have had poor safety and tolerability profiles. However, second generation AEDs with newer mechanisms of action, such as Keppra (levetiracetam), Zonegran (zonisamide) and Vimpat (lacosamide), have signaled a shift in the last decade with improved tolerability and efficacy. Recent approvals, including Fycompa (perampanel) and Trobalt (retigabine) have continued this trend by focusing on new molecular targets. Order a copy of Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability research report at http://www.reportsnreports.com/Purchase.aspx?name=276612 .

The Asia-Pacific NSCLC therapeutics industry report discusses marketed products like Alimta (pemetrexed disodium) - Eli Lilly and Company, Abraxane (nab-paclitaxel) - Celgene, Iressa (gefitinib) - AstraZeneca, Tarceva (erlotinib hydrochloride) - F. Hoffmann-La Roche, Xalkori (crizotinib) - Pfizer, Avastin (bevacizumab) - F. Hoffmann-La Roche and Gilotrif (afatinib) - Boehringer Ingelheim. Promising drug candidates in the pipeline discussed in this research include Ramucirumab (IMC-1121B) - Eli Lilly and Company, Necitumumab (IMC-11F8) - Eli Lilly and Company, Onartuzumab (MetMab) - F. Hoffmann-La Roche, Ganetespib (STA-9090) - Synta, Nintedanib (BIBF1120) - Boehringer Ingelheim, Dacomitinib (PF-00299804) - Pfizer, LDK378 - Novartis, Yervoy (ipilimumab) - Bristol-Myers Squibb and Nivolumab (BMS-936558/ONO-4538) - Bristol Myers Squibb. Order a copy of NSCLC Therapeutics in Asia-Pacific Markets to 2019 - Personalized Therapies Focus on Untapped Segment of Squamous Cell Carcinoma to Expand Treatment Pool research report at http://www.reportsnreports.com/Purchase.aspx?name=276615 .

Explore more reports on the pharmaceuticals market and healthcare industry at http://www.reportsnreports.com/market-research/healthcare/ .

About Us:

ReportsnReports.com is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:

Priyank Tiwari

TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252

Tel: +1-888-391-5441
[email protected]

Connect With Us on:

Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689

LinkedIn: http://www.linkedin.com/company/reportsnreports

Twitter: https://twitter.com/marketsreports

Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/

SOURCE ReportsnReports.com

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
SYS-CON Events announced today that Super Micro Computer, Inc., a global leader in compute, storage and networking technologies, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Supermicro (NASDAQ: SMCI), the leading innovator in high-performance, high-efficiency server technology, is a premier provider of advanced server Building Block Solutions® for Data Center, Cloud Computing, Enterprise IT, Hadoop/...
This talk centers around how to automate best practices in a multi-/hybrid-cloud world based on our work with customers like GE, Discovery Communications and Fannie Mae. Today’s enterprises are reaping the benefits of cloud computing, but also discovering many risks and challenges. In the age of DevOps and the decentralization of IT, it’s easy to over-provision resources, forget that instances are running, or unintentionally expose vulnerabilities.
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists will look at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deli...
In order to meet the rapidly changing demands of today’s customers, companies are continually forced to redefine their business strategies in order to meet these needs, stay relevant and continue to see profitable growth. IoT deployment and development is integral in this transformation, and today businesses are increasingly seeing the value of investing their resources into IoT deployments. These technologies are able increase ROI through projects such as connecting supply chains or enabling sm...
For financial firms, the cloud is going to increasingly become a crucial part of dealing with customers over the next five years and beyond, particularly with the growing use and acceptance of virtual currencies. There are new data storage paradigms on the horizon that will deliver secure solutions for storing and moving sensitive financial data around the world without touching terrestrial networks. In his session at 20th Cloud Expo, Cliff Beek, President of Cloud Constellation Corporation, w...
In his opening keynote at 20th Cloud Expo, Michael Maximilien, Research Scientist, Architect, and Engineer at IBM, will motivate why realizing the full potential of the cloud and social data requires artificial intelligence. By mixing Cloud Foundry and the rich set of Watson services, IBM's Bluemix is the best cloud operating system for enterprises today, providing rapid development and deployment of applications that can take advantage of the rich catalog of Watson services to help drive insigh...
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
IBM helps FinTechs and financial services companies build and monetize cognitive-enabled financial services apps quickly and at scale. Hosted on IBM Bluemix, IBM’s platform builds in customer insights, regulatory compliance analytics and security to help reduce development time and testing. In his session at 20th Cloud Expo, Tom Eck, Industry Platforms CTO at IBM Cloud, will discuss how these tools simplify the time-consuming tasks of selection, mapping and data integration, allowing developers ...
Most DevOps journeys involve several phases of maturity. Research shows that the inflection point where organizations begin to see maximum value is when they implement tight integration deploying their code to their infrastructure. Success at this level is the last barrier to at-will deployment. Storage, for instance, is more capable than where we read and write data. In his session at @DevOpsSummit at 20th Cloud Expo, Josh Atwell, a Developer Advocate for NetApp, will discuss the role and value...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend @CloudExpo | @ThingsExpo, June 6-8, 2017, at the Javits Center in New York City, NY and October 31 - November 2, 2017, Santa Clara Convention Center, CA. Learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
You know you need the cloud, but you’re hesitant to simply dump everything at Amazon since you know that not all workloads are suitable for cloud. You know that you want the kind of ease of use and scalability that you get with public cloud, but your applications are architected in a way that makes the public cloud a non-starter. You’re looking at private cloud solutions based on hyperconverged infrastructure, but you’re concerned with the limits inherent in those technologies.
As enterprise cloud becomes the norm, businesses and government programs must address compounded regulatory compliance related to data privacy and information protection. The most recent, Controlled Unclassified Information and the EU’s GDPR have board level implications and companies still struggle with demonstrating due diligence. Developers and DevOps leaders, as part of the pre-planning process and the associated supply chain, could benefit from updating their code libraries and design by in...
SYS-CON Events announced today that EARP Integration will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. EARP Integration is a passionate software house. Since its inception in 2009 the company successfully delivers smart solutions for cities and factories that start their digital transformation. EARP provides bespoke solutions like, for example, advanced enterprise portals, business intelligence systems an...